bioAffinity Technologies, Inc.

BIAF

Explore Our Financial Data > Companies > bioAffinity Technologies, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
BIAF
CIK0001712762
SIC8731
SectorServices
Industry CategoryBusiness Services
Industry GroupServices – Research, Development, Testing Labs

Contact

Address3300 NACOGDOCHES ROAD, SUITE 216, SAN ANTONIO, TX, 78217
Website bioaffinitytech.com
Phone210-698-5334
CEOMaria Zannes
Employees10

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$8.81 million
Pre-Tax Income$-9.72 million
Net Income$-9.74 million
Net Income to Common$-9.74 million
EPS$-0.71
View All
Balance Sheet
Cash$444,706.00
Assets$5.55 million
Liabilities$4.11 million
Common Equity$1.44 million
Liabilities & Equity$5.55 million
View All
Cash Flow Statement
Net Income$-9.74 million
Cash From Operating Activities$-6.56 million
Cash From Investing Activities$-88,482.00
Cash From Financing Activities$4.64 million
Change in Cash$-2.01 million
View All
Calculations
NOPAT$-6.74 million
EBITDA$-9.04 million
Price to EarningsN/A
Price to Book$5.56
ROE-290.85%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

SAN ANTONIO, July 29, 2025--CyPath® Lung detects a rare mucinous adenocarcinoma at Stage 1A in a high-risk individual whose previous tests suggested a low probability of cancer.

Article Link

Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools

SAN ANTONIO, July 23, 2025--CyPath® Lung detected a Stage 1A neuroendocrine tumor in a patient's lung when imaging and other adjuvant tools could not.

Article Link

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic

SAN ANTONIO, July 22, 2025--Canada grants bioAffinity Technologies new patent that protects its proprietary technology that powers its flagship product, CyPath® Lung

Article Link

bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic

SAN ANTONIO, July 15, 2025--bioAffinity Technologies has received notification of allowance from China for a patent on its technology for predicting the likelihood of lung cancer

Article Link

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging

SAN ANTONIO, July 09, 2025--bioAffinity Technologies' CyPath® Lung detects Stage 1A lung cancer when imaging was inconclusive and other diagnostics were contraindicated.

Article Link